Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etifelmine SCHEMBL31415091 | 0.98 | ESR1 (0.44) | ESR1CYP19A1ESR2CYP3A4ATM | |
| Etifelmine SCHEMBL1649891 | 0.96 | ESR1 (0.43) | ESR1CYP19A1ESR2CYP3A4ATM | |
| SCHEMBL11787805 | 0.86 | ESR1 (0.52) | ESR1CYP19A1ESR2CYP3A4ATM | |
| SCHEMBL5278371 | 0.81 | ESR1 (0.48) | ESR1CYP19A1ESR2CYP3A4ATM | |
| SCHEMBL5278366 | 0.78 | ESR1 (0.46) | ESR1CYP19A1ESR2CYP3A4ATM | |
| SCHEMBL10601630 | 0.75 | ESR1 (0.50) | ESR1CYP19A1ESR2CYP3A4ATM | |
| SCHEMBL7596993 | 0.72 | ESR1 (0.49) | ESR1CYP19A1ESR2 | |
| SCHEMBL7596988 | 0.72 | ESR1 (0.49) | ESR1CYP19A1ESR2 | |
| SCHEMBL10979622 | 0.72 | ESR1 (0.62) | ESR1CYP19A1ESR2PTGS2 | |
| SCHEMBL10979621 | 0.72 | ESR1 (0.62) | ESR1CYP19A1ESR2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 734 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4134091-B1 | FRACTION EXTRACT OF MELISSA OFFICINALIS LEAVES AND NOVEL PHARMACEUTICAL COMPOSITION INCLUDING SAME | ANGIOLAB INC (KR) | 2025-12-10 | — | — | EP | claimed |
| CN-120129690-A | Dual receptor targeted radioligands and uses thereof | 辐联科技香港有限公司 | 2025-06-10 | — | — | CN | claimed |
| CN-119475849-A | Main aftershock anti-seismic toughness rapid evaluation method and system based on circulation-transducer network | 东南大学 | 2025-02-18 | — | — | CN | claimed |
| WO-2024157264-A9 | PLANT HEALTH / PLANT VIGOR IMPROVING MIXTURE OF INSECTICIDES | ADAMA MAKHTESHIM LTD. (IL) | 2024-10-24 | — | — | WO | claimed |
| US-12111313-B2 | Chelator-coated field effect transistor and devices and methods using same | Autonomous Medical Devices Inc. (US) | 2024-10-08 | — | — | US | claimed |
| WO-2024157264-A1 | PLANT HEALTH / PLANT VIGOR IMPROVING MIXTURE OF INSECTICIDES | ADAMA MAKHTESHIM LTD. (IL) | 2024-08-02 | — | — | WO | claimed |
| US-20240192208-A1 | SERUM ANTIBODY PROFILING FOR LEPTOSPIROSIS | SERIMMUNE INC. | 2024-06-13 | — | — | US | claimed |
| CN-117910342-A | Main aftershock earthquake structure vulnerability prediction method based on multilayer residual GRU network | 东南大学 | 2024-04-19 | — | — | CN | claimed |
| CN-117593056-A | Transaction evaluation method and device, storage medium and electronic equipment | 支付宝(杭州)信息技术有限公司 | 2024-02-23 | — | — | CN | claimed |
| CN-115836850-A | PWV data analysis system and method for arterial blood flow characteristic parameters | 智谷医疗科技（广州）有限公司 | 2023-03-24 | — | — | CN | claimed |
| US-6555136-B2 | First, second and optionally third dosage units, with each dosage unit having a different drug release profile. | PHARMAQUEST, LTD. (BM) | 2003-04-29 | — | — | US | claimed |
| WO-2003013514-A1 | IMPROVING NEUROLOGICAL FUNCTIONS | CARN-AWARE LLC (US) | 2003-02-20 | — | — | WO | claimed |
| US-20020058061-A1 | Pharmaceutical dosage form for pulsatile delivery of methylphenidate | MIDHA KAMAL K (CA) | 2002-05-16 | — | — | US | claimed |
| EP-1191924-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF (D-THREO)-METHYLPHENIDATE AND A SECOND CNS STIMULANT | Pharmaquest Limited (BM) | 2002-04-03 | — | — | EP | claimed |
| EP-1165054-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF METHYLPHENIDATE | Pharmaquest Limited (BM) | 2002-01-02 | — | — | EP | claimed |
| US-6217904-B1 | MIXTURES; ADMINISTERING IN CYCLES | PHARMAQUEST LTD. (BM) | 2001-04-17 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000059481-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT | PHARMAQUEST LTD. (BM) | 2000-10-12 | — | — | WO | claimed |
| WO-2000059479-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF METHYLPHENIDATE | PHARMAQUEST LTD. (BM) | 2000-10-12 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058061-A1 | Pharmaceutical dosage form for pulsatile delivery of methylphenidate | SLC18A1, SLC6A3, CRH | ESR1 3914/4885CYP19A1 2446/4885ESR2 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.